Warhound came out of stealth on Wednesday with $200 million in funding and a mission to create “elite working dogs” equipped with "advanced body armor."

The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.

Contracts tied to elections in Ethiopia and Romania saw massive trading volumes after the outcomes were decided. “It’s obviously some form of volume manipulation,” one expert says.